Glaxosmithkline Pharmaceuticals cash flow

Latest FY26

Cash from operations: ₹903cr−30.0% on FY25
Capital spending: ₹55.3cr+140.1% on FY25
Free cash flow: ₹848cr−33.1% on FY25
Cash from financing: −₹737cr−₹769 cr in FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Changes in working capital
Adjustments to reconcile profit — non-cash items						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	—	66.4	66.8	69.7	65.8
	—	2.7	1.3	1.8	1.8
	—	−56.7	−70.8	−67.5	−69.4
	—	0.1	0.0	0.0	0.0
	—	1.9	2.4	0.6	−7.4
	—	−79.6	−68.1	−49.7	−30.8
	—	−20.7	−4.7	144	5.1
	—	24.2	43.3	−65.1	74.7
	—	17.6	−72.9	−30.3	20.2
	—	13.4	59.1	−11.8	−43.8
	—	−139	77.0	190	−153
	—	−18.2	57.3	15.2	−25.3
	—	3.7	21.0	−37.2	81.6
Cash from operating activities
	1,449	1,406	1,260	816	836
	—	−184	112	159	−80.6
	—	1,222	1,372	976	756
	—	0.0	0.0	−139	−6.8
	—	319	81.7	254	265
	—	903	1,290	582	484
Cash from investing activities
	—	55.3	23.0	31.2	44.0
	—	1.4	1.0	2.8	0.0
	—	0.0	0.0	0.0	1.5
	—	0.0	0.0	25.0	100
	—	0.0	0.0	95.0	220
	—	119	118	93.4	63.0
	—	332	−142	−126	667
	—	397	−45.8	8.7	808
Cash from financing activities
	—	23.1	19.9	19.7	18.3
	—	0.0	0.1	0.2	−0.4
	—	714	749	542	1,526
	—	−737	−769	−561	−1,543
	—	563	475	29.2	−251
	—	563	475	29.2	−251
	—	1,102	539	64.2	34.9
Reference items
	1,354	1,309	1,177	909	804
	34.2%	34.3%	31.4%	26.3%	24.7%
	848	848	1,267	551	440
	—	848	1,267	551	—
	₹50.06	₹50.06	₹74.78	₹32.51	₹25.98
	49.90×	—	—	—	—
	—	0.87×	1.39×	0.99×	0.79×
	—	319	81.7	254	265
	—	0.0	0.1	0.2	0.4

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

GLAXO₹2,498.00

Glaxosmithkline Pharmaceuticals Ltd.

· Pharma & Health

₹ CrorePeersPFIZER ABBOTINDIA MEDANTA ANTHEM AJANTPHARM IPCALAB GLENMARK BIOCONMcap ₹42,319 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation	65.8	69.7	66.8	66.4	—
+ Finance Costs	1.8	1.8	1.3	2.7	—
+ Interest Income	-69.4	-67.5	-70.8	-56.7	—
+ Fair Value (Gains) / Losses	0.0	0.0	0.0	0.1	—
+ Other Non-cash Items	-7.4	0.6	2.4	1.9	—
+ Other — Cash Effects are Investing / Financing	-30.8	-49.7	-68.1	-79.6	—
+ Other Reconciling Items	5.1	143.6	-4.7	-20.7	—
Changes in Working Capital
+ Inventories	74.7	-65.1	43.3	24.2	—
+ Trade Receivables — Current	20.2	-30.3	-72.9	17.6	—
+ Other Current Assets	-43.8	-11.8	59.1	13.4	—
+ Trade Payables — Current	-153.2	190.1	77.0	-138.9	—
+ Other Current Liabilities	-25.3	15.2	57.3	-18.2	—
+ Provisions — Current	81.6	-37.2	21.0	3.7	—
Cash from Operating Activities
Profit Before Tax (per I/S)	836.4	816.2	1,259.9	1,406.0	1,449.5
+ Total Adjustments (incl. Working Capital)	-80.6	159.5	111.7	-184.0	—
Cash from Operations (pre-tax)	755.8	975.7	1,371.6	1,222.0	—
+ Other Inflows / (Outflows) — Operating	-6.8	-139.5	0.0	0.0	—
+ Income Taxes Paid	264.7	254.2	81.7	318.7	—
Cash from Operating Activities	484.2	582.0	1,289.9	903.3	—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)	44.0	31.2	23.0	55.3	—
+ Disp of Fixed Assets	0.0	2.8	1.0	1.4	—
+ Disp of Investment Property	1.5	0.0	0.0	0.0	—
+ Loans & Advances Made	100.0	25.0	0.0	0.0	—
+ Loans & Advances Repaid	220.0	95.0	0.0	0.0	—
+ Interest Received — Investing	63.0	93.4	118.3	119.1	—
+ Other Inflows / (Outflows) — Investing	667.5	-126.3	-142.1	331.7	—
Cash from Investing Activities	807.9	8.7	-45.8	397.0	—
Cash from Financing Activities
+ Payment of Lease Liabilities	18.3	19.7	19.9	23.1	—
+ Interest Paid	-0.4	0.2	0.1	0.0	—
+ Dividends Paid	1,525.5	541.6	749.4	714.0	—
Cash from Financing Activities	-1,543.3	-561.5	-769.4	-737.1	—
Net Changes in Cash (pre-FX)	-251.3	29.2	474.7	563.2	—
Net Changes in Cash	-251.3	29.2	474.7	563.2	—
Closing Cash	34.9	64.2	538.8	1,102.1	—
Reference Items
EBITDA	804.3	908.7	1,177.4	1,309.2	1,353.5
EBITDA Margin %	24.73	26.31	31.40	34.26	34.22
Free Cash Flow (CFO − Capex)	440.2	550.8	1,266.9	848.0	848.0
Free Cash Flow to Equity	—	550.6	1,266.8	848.0	—
Free Cash Flow per Basic Share	25.98	32.51	74.78	50.06	50.06
Price to Free Cash Flow	—	—	—	—	49.90
Cash Flow to Net Income	0.79	0.99	1.39	0.87	—
Cash Paid for Taxes	264.7	254.2	81.7	318.7	—
Cash Paid for Interest	0.4	0.2	0.1	0.0	—

As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.